Early asset assessment informing indication development
Goal
The client had an ongoing phase 2b read-out in a rare diseases dermatology indication for a biologic that will be launched in another immunology indication. In anticipation of the 52 weeks data read-out the client wanted to understand the unmet needs, prioritize the value drivers, assess the future competitors and derive the strategic implications for the future clinical development, by working closely with the global and US cross-functional teams.
